These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 29527939)

  • 1. Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
    El Rassy E; Bakouny Z; Assi T; Kattan J
    Future Oncol; 2018 Apr; 14(9):891-895. PubMed ID: 29527939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
    Tamura K
    Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
    Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
    J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
    Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
    Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
    Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
    Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
    Hecht KA; Selby C
    Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Kwapisz D
    Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
    Guo Q; Lin X; Ye L; Xu R; Dai Y; Zhang Y; Chen Q
    Target Oncol; 2019 Apr; 14(2):139-148. PubMed ID: 30941621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances of highly selective CDK4/6 inhibitors in breast cancer.
    Xu H; Yu S; Liu Q; Yuan X; Mani S; Pestell RG; Wu K
    J Hematol Oncol; 2017 Apr; 10(1):97. PubMed ID: 28438180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
    Vidula N; Rugo HS
    Clin Breast Cancer; 2016 Feb; 16(1):8-17. PubMed ID: 26303211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer.
    Asghar US; Kanani R; Roylance R; Mittnacht S
    JCO Precis Oncol; 2022 Jan; 6():e2100002. PubMed ID: 35005994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment.
    Li J; Jiang J; Wu J; Bao X; Sanai N
    Clin Pharmacol Ther; 2021 Feb; 109(2):494-506. PubMed ID: 32799335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC; Lee SS; Abraham J
    Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.